Board of Directors
Michael Goldberg, MD, MPH, President, Director: Mike is President and Co-Chair of Research of the RYR-1 Foundation. He is a neuroradiologist and is the Director of Neuroradiology at the Allegheny Health Network. He is an Associate Professor at Drexel University College of Medicine. He can be reached at firstname.lastname@example.org.
Morton Goldberg, MD, FACS, Vice President, Director: Along with Mike, Mort is the Co-Chair of Research. He is also an ophthalmologist specializing in retinal disease and genetics. He is the Joseph Green Professor of Ophthalmology at the Johns Hopkins School of Medicine and the Director Emeritus of the Wilmer Eye Institute. He is a member of the Institute of Medicine of the National Academies of Science of the United States.
Lindsay Goldberg, RN, Secretary & Treasurer, Director: Lindsay is also the Executive Assistant for the RYR-1 Foundation. She is a registered nurse who worked for 10 years specializing in Pediatric Cardiac Intensive Care. She can be reached at email@example.com.
Michael Legum, Assistant Treasurer, Director: Michael is a senior portfolio manager for Park Circle Investments, a Baltimore based private investment company. Prior to Park Circle, he worked in the film business, spending five years at New Line Cinema. He is a graduate of the University of Pennsylvania with a B.A. in English.
Allison Garrott Braswell, MS, EdS, Director: Allison attended Vanderbilt University, and then, earned her Educational Specialist degree in School Psychology from the University of Memphis. She and her husband, Bo, have raised three children in Memphis, Tennessee, and she has worked as a trustee and volunteer for several community organizations. Allison has a dominant RYR-1 mutation.
Myrna Goldberg, MSW, Director: Myrna is a retired social worker, having previously worked in hospital, protective service, and school social work settings. She serves on the Board of Advisors of the University of Maryland School of Social Work, is an active member of the Baltimore Women’s Giving Circle, and is a docent at the Baltimore Museum of Art.
Justin C. McArthur, MBBS, MPH, FAAN, Director: Dr. Justin McArthur is the Neurologist-in-Chief at the Johns Hopkins Hospital and John W. Griffin Professor of Neurology at the Johns Hopkins University School of Medicine. He is also a Professor of Pathology, Medicine, and Epidemiology. He has become nationally and internationally recognized for his work in the epidemiology and treatment of HIV infection, multiple sclerosis, and other neurological infections and immune-mediated neurological disorders.
Emily Pedersen, Director: Emily worked as a Recreation Therapist and Child Life Specialist at Weisman Children's Rehabilitation Hospital for 8 years. She has participated in and organized fundraising runs to support research for RYR-1. Emily has a daughter who was diagnosed with recessive Central Core Disease caused by RYR-1 mutations.
Randolph Pepper, CPA, Director: Randy is recently retired as the Director of Finance & Accounting for Central Processing Services, LLC, a privately held company in suburban Detroit. He has a BA degree from the University of Michigan, and a MBA from Wayne State University. He has over 30 years experience in a variety of Controller/CFO positions for mid-size privately held companies.
Jennifer Ryan, MBA, Director: She is also a trustee of the Schooner Foundation and has an MBA in Operational Management from Simmons College. She is the former COO of Integral Resources, a telemarketing firm specializing in small donor acquisition for nonprofits. Both she and her daughter have Central Core Disease (CCD), a form of RYR-1 muscle disease that is due to a mutation in the RYR-1 gene. She can be reached at firstname.lastname@example.org.
Donald J. Zack, MD, PhD, Director: Dr. Donald Zack is the Guerrieri Family Professor of Genetic Engineering and Molecular Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. His research concerns the mechanisms of retinal degenerative disease and glaucoma, and efforts to develop new drug and stem cell-based therapeutic approaches.